JP2015503623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503623A5 JP2015503623A5 JP2014552325A JP2014552325A JP2015503623A5 JP 2015503623 A5 JP2015503623 A5 JP 2015503623A5 JP 2014552325 A JP2014552325 A JP 2014552325A JP 2014552325 A JP2014552325 A JP 2014552325A JP 2015503623 A5 JP2015503623 A5 JP 2015503623A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- romidepsin
- amount
- etoh
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586066P | 2012-01-12 | 2012-01-12 | |
| US61/586,066 | 2012-01-12 | ||
| PCT/US2013/021212 WO2013106696A1 (en) | 2012-01-12 | 2013-01-11 | Romidepsin formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503623A JP2015503623A (ja) | 2015-02-02 |
| JP2015503623A5 true JP2015503623A5 (https=) | 2016-03-03 |
| JP6170946B2 JP6170946B2 (ja) | 2017-07-26 |
Family
ID=47604232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552325A Active JP6170946B2 (ja) | 2012-01-12 | 2013-01-11 | ロミデプシン製剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20130184225A1 (https=) |
| EP (1) | EP2802340B1 (https=) |
| JP (1) | JP6170946B2 (https=) |
| CN (1) | CN104168908A (https=) |
| AU (1) | AU2013201937B8 (https=) |
| CA (1) | CA2863291A1 (https=) |
| MX (1) | MX2014008390A (https=) |
| WO (1) | WO2013106696A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630311A (en) * | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN106137980B (zh) * | 2015-03-31 | 2021-04-13 | 深圳翰宇药业股份有限公司 | 一种罗米地辛脂微球制剂及其制备方法 |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| KR20200141446A (ko) * | 2018-04-05 | 2020-12-18 | 타베다 세라퓨틱스, 인코포레이티드 | 감소된 3급-부탄올 수준을 갖는 약제학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
| JPH0764872A (ja) | 1993-08-26 | 1995-03-10 | Fujitsu Ten Ltd | データ記憶制御装置 |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| HK1040062A1 (zh) * | 1999-03-03 | 2002-05-24 | Eli Lilly And Company | 含有成胶束表面活性剂的棘白菌素药物配方 |
| US7396665B2 (en) | 2000-09-01 | 2008-07-08 | Astellas Pharma, Inc. | Method of producing FR901228 |
| DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| GB0511266D0 (en) | 2005-06-02 | 2005-07-13 | Trust | Chemical compounds |
| EP2040731A4 (en) * | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| EP2450049A1 (en) * | 2006-12-29 | 2012-05-09 | Gloucester Pharmaceuticals, Inc. | Romidepsin-based treatments for cancer |
| WO2008127659A2 (en) * | 2007-04-13 | 2008-10-23 | University Of Texas Southwestern Medical Center | Combination therapy for cancer |
| JP2010105965A (ja) * | 2008-10-30 | 2010-05-13 | Taiyo Yakuhin Kogyo Kk | バンコマイシン製剤 |
| SG10201407724YA (en) * | 2009-11-23 | 2014-12-30 | Cubist Pharm Inc | Daptomycin compositions and related methods |
| SG10201505475XA (en) | 2010-07-12 | 2015-09-29 | Celgene Corp | Romidepsin solid forms and uses thereof |
-
2013
- 2013-01-11 EP EP13701320.7A patent/EP2802340B1/en active Active
- 2013-01-11 JP JP2014552325A patent/JP6170946B2/ja active Active
- 2013-01-11 MX MX2014008390A patent/MX2014008390A/es unknown
- 2013-01-11 CN CN201380013811.9A patent/CN104168908A/zh active Pending
- 2013-01-11 AU AU2013201937A patent/AU2013201937B8/en not_active Ceased
- 2013-01-11 US US13/740,063 patent/US20130184225A1/en not_active Abandoned
- 2013-01-11 WO PCT/US2013/021212 patent/WO2013106696A1/en not_active Ceased
- 2013-01-11 CA CA2863291A patent/CA2863291A1/en not_active Abandoned
-
2014
- 2014-10-17 US US14/517,716 patent/US20150051157A1/en not_active Abandoned
-
2016
- 2016-09-06 US US15/257,771 patent/US20160367625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| JP2015078230A5 (https=) | ||
| JP2015502926A5 (https=) | ||
| JP2014507446A5 (https=) | ||
| JP2015503623A5 (https=) | ||
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX378315B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos | |
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| JP2014533667A5 (https=) | ||
| BR112012026289A2 (pt) | composto orgânico para uso no tratamento de câncer do fígado | |
| JP2016510019A5 (https=) | ||
| JP2016533366A5 (https=) | ||
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| JP2012502037A5 (https=) | ||
| JP2011105738A5 (https=) | ||
| JP2015508103A5 (https=) | ||
| JP2017513917A5 (https=) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| JP2014525449A5 (https=) | ||
| WO2015033302A3 (en) | Fulvestrant compositions | |
| JP2014531401A5 (https=) | ||
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. |